Publicacións en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (68)

2022

  1. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

    Journal of Infectious Diseases, Vol. 226, pp. S29-S37

  2. Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection

    The Journal of infectious diseases, Vol. 226, Núm. 1, pp. S45-S54

  3. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations

    Pathogens and Global Health, Vol. 116, Núm. 2, pp. 85-98

  4. Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

    Journal of Infectious Diseases, Vol. 226, pp. S135-S141

  5. Incidence of herpes zoster and its complications in ≥ 50-year-old Spanish adults: A prospective cohort study

    Vacunas, Vol. 23, Núm. 3, pp. 165-173

  6. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

    Open Forum Infectious Diseases, Vol. 9, Núm. 10

  7. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

    Journal of Infectious Diseases, Vol. 226, pp. S130-S134

  8. Range of invasive meningococcal disease sequelae and health economic application – a systematic and clinical review

    BMC Public Health, Vol. 22, Núm. 1

  9. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

    Clinical Infectious Diseases, Vol. 74, Núm. 8, pp. 1459-1467

  10. The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative

    Expert Review of Vaccines, Vol. 21, Núm. 12, pp. 1701-1710

  11. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

    Journal of Clinical Epidemiology, Vol. 147, pp. 11-20

2021

  1. Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review

    Dermatology and Therapy, Vol. 11, Núm. 4, pp. 1119-1126